Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group | Zendy

Peter Dubsky | Zendy; R. Jakesz | Zendy; Brigitte Mlineritsch | Zendy; Sabine Pöstlberger | Zendy; Hellmut Samonigg | Zendy; W. Kwasny | Zendy; Christoph Tausch | Zendy; Herbert Stöger | Zendy; K. Haider | Zendy; Florian Fitzal | Zendy; Christian F. Singer | Zendy; M. Stierer | Zendy; P. Sevelda | Zendy; G. Luschin-Ebengreuth | Zendy; Susanne Taucher | Zendy; Margaretha Rudas | Zendy; Rupert Bartsch | Zendy; Günther Steger | Zendy; Richard Greil | Zendy; Lidija Filipcic | Zendy; Michael Gnant | Zendy

Open Access

Tamoxifen and Anastrozole As a Sequencing Strategy: A Randomized Controlled Trial in Postmenopausal Patients With Endocrine-Responsive Early Breast Cancer From the Austrian Breast and Colorectal Cancer Study Group

Author(s) -

Peter Dubsky,

R. Jakesz,

Brigitte Mlineritsch,

Sabine Pöstlberger,

Hellmut Samonigg,

W. Kwasny,

Christoph Tausch,

Herbert Stöger,

K. Haider,

Florian Fitzal,

Christian F. Singer,

M. Stierer,

P. Sevelda,

G. Luschin-Ebengreuth,

Susanne Taucher,

Margaretha Rudas,

Rupert Bartsch,

Günther Steger,

Richard Greil,

Lidija Filipcic,

Michael Gnant

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.36.8993

Subject(s) - medicine , anastrozole , tamoxifen , breast cancer , oncology , hazard ratio , adverse effect , colorectal cancer , cancer , gynecology , confidence interval

Anastrozole (ANA) alone delivers significant disease-free survival benefits over tamoxifen (TAM) monotherapy in postmenopausal women with early estrogen receptor-positive breast cancer. The ABCSG-8 (Austrian Breast and Colorectal Cancer Study Group 8) study is a large phase III clinical trial addressing the sequence strategy containing ANA in comparison with 5 years of TAM in a low- to intermediate-risk group of postmenopausal patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research